{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:19:22Z","timestamp":1790180362363,"version":"4.1.0"},"reference-count":43,"publisher":"Japan Neurosurgical Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2018]]},"DOI":"10.2176\/nmc.oa.2018-0111","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T17:33:19Z","timestamp":1542735199000},"page":"487-494","source":"Crossref","is-referenced-by-count":29,"title":["Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas \u2013 A Pilot Study"],"prefix":"10.2176","volume":"58","author":[{"given":"Hiroyuki","family":"SHIBA","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"TAKEUCHI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"HIRAMATSU","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomasa","family":"FURUSE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naosuke","family":"NONOGUCHI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"KAWABATA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"KUROIWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"KONDO","sequence":"additional","affiliation":[{"name":"Kyoto University Research Reactor Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"SAKURAI","sequence":"additional","affiliation":[{"name":"Kyoto University Research Reactor Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"SUZUKI","sequence":"additional","affiliation":[{"name":"Kyoto University Research Reactor Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"ONO","sequence":"additional","affiliation":[{"name":"Kyoto University Research Reactor Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"OUE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Ehime Prefectural Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"ISHIKAWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tsukuba University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"MICHIUE","sequence":"additional","affiliation":[{"name":"Neutron Therapy Research Center, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"MIYATAKE","sequence":"additional","affiliation":[{"name":"Section for Advanced Medical Development, Cancer Center, Osaka Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. <i>J Clin Oncol<\/i> 25: 2601\u20132606, 2007","DOI":"10.1200\/JCO.2006.08.1661"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Miyatake S, Kawabata S, Kajimoto Y, et al.: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. <i>J Neurosurg<\/i> 103: 1000\u20131009, 2005","DOI":"10.3171\/jns.2005.103.6.1000"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Miyatake S, Kawabata S, Yokoyama K, et al.: Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. <i>J Neurooncol<\/i> 91: 199\u2013206, 2009","DOI":"10.1007\/s11060-008-9699-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Barth RF, Vicente MG, Harling OK, et al.: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. <i>Radiat Oncol<\/i> 7: 146, 2012","DOI":"10.1186\/1748-717X-7-146"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Miyatake S, Furuse M, Kawabata S, et al.: Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. <i>Neuro-oncology<\/i> 15: 650\u2013655, 2013","DOI":"10.1093\/neuonc\/not020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Miyatake S, Kawabata S, Nonoguchi N, et al.: Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. <i>Neuro-oncology<\/i> 11: 430\u2013436, 2009","DOI":"10.1215\/15228517-2008-107"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Nonoguchi N, Miyatake S, Fukumoto M, et al.: The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. <i>J Neurooncol<\/i> 105: 423\u2013431, 2011","DOI":"10.1007\/s11060-011-0610-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. <i>J Neurooncol<\/i> 102: 471\u2013475, 2011","DOI":"10.1007\/s11060-010-0333-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Furuse M, Nonoguchi N, Kuroiwa T, et al.: A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis<sup>\u2020<\/sup>. <i>Neurooncol Pract<\/i> 3: 272\u2013280, 2016","DOI":"10.1093\/nop\/npv064"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Levin VA, Bidaut L, Hou P, et al.: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. <i>Int J Radiat Oncol Biol Phys<\/i> 79: 1487\u20131495, 2011","DOI":"10.1016\/j.ijrobp.2009.12.061"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M: Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. <i>Radiat Oncol<\/i> 9: 6, 2014","DOI":"10.1186\/1748-717X-9-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Perez-Torres CJ, Yuan L, Schmidt RE, et al.: Specificity of vascular endothelial growth factor treatment for radiation necrosis. <i>Radiother Oncol<\/i> 117: 382\u2013385, 2015","DOI":"10.1016\/j.radonc.2015.09.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Schnell O, Thorsteinsdottir J, Fleischmann DF, et al.: Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. <i>J Neurooncol<\/i> 130: 591\u2013599, 2016","DOI":"10.1007\/s11060-016-2267-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Anderson JC, Duarte CW, Welaya K, et al.: Kinomic exploration of temozolomide and radiation resistance in glioblastoma multiforme xenolines. <i>Radiother Oncol<\/i> 111: 468\u2013474, 2014","DOI":"10.1016\/j.radonc.2014.04.010"},{"key":"15","unstructured":"15) Imahori Y, Ueda S, Ohmori Y, et al.: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. <i>Clin Cancer Res<\/i> 4: 1825\u20131832, 1998"},{"key":"16","unstructured":"16) Imahori Y, Ueda S, Ohmori Y, et al.: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. <i>Clin Cancer Res<\/i> 4: 1833\u20131841, 1998"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kawabata S, Miyatake S, Kajimoto Y, et al.: The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. <i>J Neurooncol<\/i> 65: 159\u2013165, 2003","DOI":"10.1023\/B:NEON.0000003751.67562.8e"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S: Boron neutron capture therapy for recurrent high-grade meningiomas. <i>J Neurosurg<\/i> 119: 837\u2013844, 2013","DOI":"10.3171\/2013.5.JNS122204"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Miyashita M, Miyatake S, Imahori Y, et al.: Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. <i>J Neurooncol<\/i> 89: 239\u2013246, 2008","DOI":"10.1007\/s11060-008-9621-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Wen PY, Macdonald DR, Reardon DA, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. <i>J Clin Oncol<\/i> 28: 1963\u20131972, 2010","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Han SJ, Rolston JD, Molinaro AM, et al.: Phase II trial of 7 days on\/7 days off temozolmide for recurrent high-grade glioma. <i>Neuro-oncology<\/i> 16: 1255\u20131262, 2014","DOI":"10.1093\/neuonc\/nou044"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Omuro A, Chan TA, Abrey LE, et al.: Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-oncology<\/i> 15: 242\u2013250, 2013","DOI":"10.1093\/neuonc\/nos295"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Mrugala MM, Engelhard HH, Dinh Tran D, et al.: Clinical practice experience with NovoTTF-100A<sup>TM<\/sup> system for glioblastoma: The Patient Registry Dataset (PRiDe). <i>Semin Oncol<\/i> 41 Suppl 6: S4\u2013S13, 2014","DOI":"10.1053\/j.seminoncol.2014.09.010"},{"key":"24","unstructured":"24) Walker MD, Gehan EA: Clinical studies in malignant gliomas and their treatment with the nitrosoureas. <i>Cancer Treat Rep<\/i> 60: 713\u2013716, 1976"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Combs SE, Gutwein S, Schulz-Ertner D, et al.: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I\/II study. <i>Strahlenther Onkol<\/i> 181: 372\u2013377, 2005","DOI":"10.1007\/s00066-005-1359-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Stupp R, Mason WP, van den Bent MJ, et al.: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain &amp; RT Groups and NCIC Clinical Trials Group. 2004","DOI":"10.1200\/jco.2004.22.90140.2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Weller M, M\u00fcller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society: Neuro-oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. <i>J Clin Oncol<\/i> 21: 3276\u20133284, 2003","DOI":"10.1200\/JCO.2003.03.509"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sneed PK, Gutin PH, Larson DA, et al.: Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. <i>Int J Radiat Oncol Biol Phys<\/i> 29: 719\u2013727, 1994","DOI":"10.1016\/0360-3016(94)90559-2"},{"key":"29","unstructured":"29) Brandes AA, Pasetto LM, Monfardini S: New drugs in recurrent high grade gliomas. <i>Anticancer Res<\/i> 20: 1913\u20131920, 2000"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Chinot OL, Wick W, Mason W, et al.: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. <i>N Engl J Med<\/i> 370: 709\u2013722, 2014","DOI":"10.1056\/NEJMoa1308345"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Gilbert MR, Dignam JJ, Armstrong TS, et al.: A randomized trial of bevacizumab for newly diagnosed glioblastoma. <i>N Engl J Med<\/i> 370: 699\u2013708, 2014","DOI":"10.1056\/NEJMoa1308573"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wick W, Gorlia T, Bendszus M, et al.: Lomustine and bevacizumab in progressive glioblastoma. <i>N Engl J Med<\/i> 377: 1954\u20131963, 2017","DOI":"10.1056\/NEJMoa1707358"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Taal W, Oosterkamp HM, Walenkamp AM, et al.: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncol<\/i> 15: 943\u2013953, 2014","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Flieger M, Ganswindt U, Schwarz SB, et al.: Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. <i>J Neurooncol<\/i> 117: 337\u2013345, 2014","DOI":"10.1007\/s11060-014-1394-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Gutin PH, Iwamoto FM, Beal K, et al.: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. <i>Int J Radiat Oncol Biol Phys<\/i> 75: 156\u2013163, 2009","DOI":"10.1016\/j.ijrobp.2008.10.043"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hundsberger T, Br\u00fcgge D, Putora PM, Weder P, Weber J, Plasswilm L: Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. <i>J Neurooncol<\/i> 112: 133\u2013139, 2013","DOI":"10.1007\/s11060-013-1044-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Niyazi M, Ganswindt U, Schwarz SB, et al.: Irradiation and bevacizumab in high-grade glioma retreatment settings. <i>Int J Radiat Oncol Biol Phys<\/i> 82: 67\u201376, 2012","DOI":"10.1016\/j.ijrobp.2010.09.002"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hayman SR, Calle JC, Jatoi A, et al.: Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies. <i>Oncology<\/i> 86: 271\u2013278, 2014","DOI":"10.1159\/000360180"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR: Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. <i>Cancer Chemother Pharmacol<\/i> 73: 1197\u20131204, 2014","DOI":"10.1007\/s00280-014-2456-2"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. <i>Eur J Cancer<\/i> 46: 439\u2013448, 2010","DOI":"10.1016\/j.ejca.2009.11.001"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. <i>J Clin Oncol<\/i> 22: 2184\u20132191, 2004","DOI":"10.1200\/JCO.2004.11.022"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. <i>N Engl J Med<\/i> 349: 427\u2013434, 2003","DOI":"10.1056\/NEJMoa021491"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. <i>Am J Kidney Dis<\/i> 49: 186\u2013193, 2007","DOI":"10.1053\/j.ajkd.2006.11.039"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/58\/12\/58_oa.2018-0111\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T15:07:53Z","timestamp":1572966473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/58\/12\/58_oa.2018-0111\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2176\/nmc.oa.2018-0111","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}